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OBJECTIVES: To evaluate the impact of golimumab (GLM)
on productivity in ankylosing spondylitis (AS) patients.
METHODS: GLM was studied in a multicenter, randomized,
placebo (PBO)-controlled study (GO-RAISE). A total of 356
patients were randomized (1.8:1.8:1 ratio) to receive subcutane-
ous GLM 50 mg or 100 mg or PBO q4wks. Patients with AS
according to the modiﬁed NY criteria (BASDAI and back pain
score each 34) were eligible. Productivity was measured on a VAS
scale (0–10 cm). Change in productivity from baseline to wk16
and wk24 was compared between groups. At wk16, patients in
the PBO or GLM 50 mg group who had <20% improvement in
total back pain and morning stiffness measures entered early
escape in a double-blind fashion. All other patients remained on
their previous medication until wk24. For GLM 50 mg or PBO
patients who entered early escape, their last observation prior to
change in treatment was carried forward for the wk24 analyses.
Observed values at wk24 were used for GLM 100 mg patients.
An ANOVA on van der Waerden normal scores was performed
for between-group differences. RESULTS: Patients in the GLM
50 mg, 100 mg, and PBO groups had similar mean  SD base-
line scores of 6.6  2.5, 6.8  2.3 and 6.3  2.5, respectively.
Mean improvement in self-reported productivity was signiﬁ-
cantly greater in the GLM 50 mg group vs. PBO at wk16
(-2.8  3.0 vs. -0.4  2.7; p < 0.001) and wk24 (-2.7  3.1 vs.
-0.5  3.0; p < 0.001), and was also signiﬁcantly greater in the
GLM 100 mg group vs. PBO at wk16 (-2.9  2.9 vs -0.4  2.7;
p < 0.001) and wk24 (-2.9  3.0 vs. -0.5  3.0; p < 0.001). The
change from baseline in productivity was similar in the GLM
50 mg and GLM 100 mg groups at wk16 and wk24. CONCLU-
SIONS: A patients treated with GLM 50 mg and 100 mg had
signiﬁcant improvement in self-reported productivity, with
improvement at wk16 maintained through wk24.
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OBJECTIVES: To develop an electronic version of the Health
Assessment Questionnaire Disability Index (HAQ-DI) for use on
a handheld computer and to assess the equivalence of the elec-
tronic and paper versions in patients with rheumatoid arthritis.
METHODS: Development of the electronic version involved sig-
niﬁcant modiﬁcation, in particular eliminating free text entry.
The conceptual framework of the scale was not altered, and the
electronic version was aligned to the original scoring scheme.
Equivalence of scores was evaluated in a crossover study in
which patients completed a series of questionnaires including the
HAQ-DI once in electronic and once in paper mode in ran-
domised order with a 45-minute interval in between. Patients
then completed a questionnaire on ease of use and acceptability
of the two modes. Agreement was assessed using intraclass cor-
relation coefﬁcients (ICC), mean differences between electronic
and paper scores, and Bland-Altman plots. RESULTS: Forty-
three patients, 12 male and 31 female, aged 32–83 years, com-
pleted the study. Overall agreements between the paper and
electronic questionnaires was excellent (HAQ-DI: ICC = 0.963).
Comparison of mean differences showed no evidence for bias in
electronic vs. paper scores. The mean difference between elec-
tronic and paper scores was 0.03 units (S.D. 0.20), correspond-
ing to 1% of the total scale length. Most patients found both
paper and electronic questionnaires easy to use, and all patients
found both modes acceptable. Six patients preferred paper, 23
preferred electronic, and 14 expressed no preference. CONCLU-
SIONS: There was excellent agreement between electronic and
paper administration of the HAQ, suggesting that migration
from paper to electronic had not led to any signiﬁcant change in
the data collected. Electronic methods of data collection were
well-liked by patients and highly acceptable. The results support
the use of the electronic version of this scale in clinical studies in
rheumatoid arthritis.
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OBJECTIVES: To develop and validate a brief generic question-
naire to assess patients’ satisfaction with pharmacological treat-
ment in chronic diseases. METHODS: An extensive literature
review was conducted to create an initial item pool of 41 ques-
tions regarding, exclusively, satisfaction with medication. Next,
two physicians and two English-Spanish translators carried out
item forward-backward translation into Spanish. Moreover,
comprehension and importance of items (C/I) were assessed by
experts’ (5 physicians, 2 nurses and 1 psychologist) and patients’
(n = 30) panels leading to an initial version of 20 items. Finally,
scale item reduction and validation (feasibility, reliability and
validity properties) of the ﬁnal SAT-Q were carried with patients
from 4 Primary Health Centres. RESULTS: In total 202 patients
(65.35% female) were collected and 196 patients (97.5%) com-
pleted the questionnaire correctly. Exploratory factorial analysis
(FA) and item-total correlation lead to a reduced ﬁnal question-
naire (13 items). Conﬁrmatory FA (oblimin rotation) revealed 1
general domain, global satisfaction (3 items, 72.35% of variance
explained, Cronbach’s a: 0.81) along with 4 speciﬁc domains
(eigenvalues >1.0): side-effects (3 items, 32.49% of variance
explained, Cronbach’s a: 0.76) oversights (2 items, 14.85%,
Cronbach’s a: 0.71), treatment effectiveness (3 items, 13.92%,
Cronbach’s a: 0.74), adherence (2 items, 10.23%, Cronbach’s a:
0.53). Overall, test-retest correlations (n = 50) were signiﬁcative
(p < 0.001): global satisfaction (0.69), treatment effectiveness
(0.63); side-effects (0.46), adherence (0.64) oversights (0.88).
Correlations between domains and Physical and Mental
Summary Components of SF-12 Health Survey were respectively:
global satisfaction (0.39 and 0.30; p < 0.001), treatment effec-
tiveness (0.33 and 0.19 p < 0.001); side-effects (0.35 and 0.35;
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p < 0.001), adherence (0.149 and 0.17 p < 0.05), oversights
(0.13; -0.01 p > 0.05). CONCLUSIONS: A brief questionnaire
to evaluate global and speciﬁc domains related to satisfaction
with medication was developed. Further investigation is needed
to test internal consistency of adherence domain and sensitivity
to change of the SAT-Q.
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OBJECTIVES: To quantify changes in productivity within and
outside home associated with meaningful improvements in physi-
cal function or reduction of fatigue in Rheumatoid Arthritis (RA)
patients treated with certolizumab pegol, the ﬁrst PEGylated,
Fc-free anti-TNF. METHODS: Physical function and fatigue
were assessed in RAPID trials using the Health Assessment
Questionnaire-Disability Index (HAQ-DI) and the Fatigue
Assessment Scale (FAS), respectively. Clinically meaningful
improvement in HAQ-DI was 0.22 points and for FAS was
1.0 point. Productivity within and outside home was evaluated
with the RA-speciﬁc Work Productivity Survey (WPS-RA).
Improvements in productivity were compared between respond-
ers and non-responders at wk12, irrespective of treatment assign-
ment, using a non-parametric bootstrap-t method. RESULTS:
For patients employed outside home, meaningful improvement in
physical function was associated with a decrease in absenteeism;
responders gained 1.95 (p  0.05) and 0.58 (NS) additional
workdays/month compared to non-responders. Physical function
improvements were associated with a decrease in presenteeism, a
reduction of 3.26 to 4.50 workdays/month with low productivity
was observed in responders compared to non-responders (p 
0.05). Meaningful reduction in fatigue in employed patients was
related to a decrease of 2.68 (NS) to 3.37 (p  0.05) workdays/
month with low productivity compared to non-responders. For
all patients, meaningful improvement in physical function was
associated with a gain of 2.11 to 4.74 additional household
workdays/month (p  0.05) and a decrease of 1.89 to 3.40
household workdays/month with low productivity compared to
non-responders (p  0.05). Meaningful reduction in fatigue was
related to a gain of 2.41 to 3.16 additional household workdays/
month (p  0.05) and a decrease of 3.59 to 3.69 household
workdays/ month with low productivity compared to non-
responders (p  0.05). CONCLUSIONS: Meaningful reduction
in fatigue in RA patients was associated with improved produc-
tivity at home, whereas physical function improvements were
associated with increased productivity both at work and at
home.
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OBJECTIVES: Normative data were collected for the Quality of
Life Assessment of Growth Hormone Deﬁciency in Adults (QoL-
AGHDA) questionnaire in the French general population in
order to improve the QoL-AGHDA scoring system and its inter-
pretability, as well as prepare for health economic assessment.
METHODS: A postal survey was conducted on a sample of
2,900 adults belonging to TNS-Healthcare permanent polling
panel and selected to be representative of the French population.
Participants were asked to complete an 8-page questionnaire
including the QoL-AGHDA questionnaire, the EuroQoL-5
Dimension (EQ-5D), a 5-point Likert scale for the participants to
rate their overall health status (OHS) and questions about their
general and medical situation. Socio-demographic data came
from the permanent polling panel. A total score was calculated
on the 25 dichotomous items of the QoL-AGHDA questionnaire,
with a lower score indicating a better QoL. The description of the
QoL-AGHDA score was performed on weighted data in order to
ensure that the respondent population was representative of the
French population. The QoL-AGHDA score was described
according to OHS of respondents. Pearson correlation coefﬁcient
with the EQ-5D index was calculated. RESULTS: The return rate
of questionnaires was 75%; 95% of respondents completed all
QoL-AGHDA items. The mean age of the population was 50.1,
with 54.1% respondents female. The mean weighted QoL-
AGHDA score was 5.05 for women and 4.18 for men; it was
4.37 for people aged 18–40 years, 4.63 for 40–60 and 5.02 above
60. When described according to respondents’ OHS, it was: 1.54
for excellent OHS, 2.87 for very good, 4.49 for good, 7.73 for
fair and 12.30 for poor OHS. Its correlation with the EQ-5D
index was –0.59. CONCLUSIONS: Reference values for the
QoL-AGHDA questionnaire have been collected for the French
general population, completing the QoL-AGHDA normative
database already available in a number of European countries.
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OBJECTIVES: Productivity loss can be deﬁned as time missed
from work due to health reasons (absenteeism) as well as the time
of impaired performance while at work (presenteeism). This
study explored the impact of health problems on presenteeism in
patients with rheumatoid arthritis (RA) compared to a healthy
comparison group. METHODS: Patients recently diagnosed
with RA were asked to participate in this cross-sectional survey.
The comparison group was formed by subjects without RA
matched on age and sex. Presenteeism was assessed by: 1) Quan-
tity and Quality Questionnaire (QQ) reporting the quantity and
quality of the work performed on the last working day, and 2) the
Work Productivity and Activity Impairment Questionnaire
General Health (WPAI-GH) measuring the degree health prob-
lems affected work productivity on the last week. Correlation
coefﬁcients between instruments were calculated and differences
between groups were tested by Mann-Witney U tests. RESULTS:
Data were available from 78 patients of which 30 (42%) had
a paid job (mean (SD) age 47 (9); 47% female; mean (SD)
number working hours per week 30 (10)); and 87 healthy
controls of which 47 (55%) had a paid job and could be used for
analysis. Demographic characteristics as well as total working
hours per week were not signiﬁcantly different between groups.
RA patients missed more days from work due to health reasons
in the last 3 months compared to the controls (11 (22) versus
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